Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
| Abstract |
|
| Authors | Roch Houot, Guillaume Cartron, Fontanet Bijou, Sophie de Guibert, Gilles A Salles, Christophe Fruchart, Krimo Bouabdallah, Marie Maerevoet, Pierre Feugier, Steven Le Gouill, Hervé Tilly, Rene-Olivier Casasnovas, Cécile Moluçon-Chabrot, Eric Van Den Neste, Pierre Zachee, Marc Andre, Christophe Bonnet, Corinne Haioun, Achiel Van Hoof, Koen Van Eygen, Lysiane Molina, Emmanuelle Nicolas-Virelizier, Philippe Ruminy, Franck Morschhauser |
| Journal | Leukemia
(Leukemia)
Vol. 33
Issue 3
Pg. 776-780
(03 2019)
ISSN: 1476-5551 [Electronic] England |
| PMID | 30291335
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Lenalidomide
- obinutuzumab
|
| Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(administration & dosage)
- Animals
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Agents, Immunological
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Humans
- Lenalidomide
(administration & dosage)
- Lymphoma
(drug therapy)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Recurrence
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|
